Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Behavioral Sciences (Basel, Switzerland)|July 28, 2026
The Double-Edged Sword Effect of Government Chatbot Empathy on Citizens' Continued Usage IntentionXuesong Li, Yangying Zhou, Muqun Hu
Advances in Therapy|March 4, 2023
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness AnalysisKun Liu, Youwen Zhu, Yangying Zhou, et al.
Biomedicines|December 23, 2023
Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric CancerKuo Kang, Xuanxuan Li, Yuanhao Peng, et al.
Cancer Cell International|October 11, 2023
AP4M1 as a prognostic biomarker associated with cell proliferation, migration and immune regulation in hepatocellular carcinomaYuanhao Peng, Xuanxuan Li, Kuo Kang, et al.
Therapeutic Advances in Medical Oncology|October 17, 2023
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trialYouwen Zhu, Kun Liu, Hong Zhu, et al.
Gynecologic Oncology|July 5, 2022
Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysisKun Liu, Youwen Zhu, Yangying Zhou, et al.
Biomedicines|May 16, 2023
Integrative Analysis of the Predictive Value of Perilipin Family on Clinical Significance, Prognosis and Immunotherapy of GliomaXuanxuan Li, Kuo Kang, Lin Shen, et al.
BMC Medicine|February 22, 2023
Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation studyYiwen Long, Lanhua Tang, Yangying Zhou, et al.
ACS Omega|February 10, 2025
Construction and Validation of a Novel Butyrylation-Related Gene Signature Related to Prognosis, Clinical Implications, and Immune Microenvironment Characterization of Hepatocellular CarcinomaWeiping Su, Yangying Zhou, Xuanxuan Li, et al.
Advances in Therapy|April 8, 2022
Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness AnalysisYouwen Zhu, Kun Liu, Dong Ding, et al.
Pageof 7